No Data
Following a 25% Decline Over Last Year, Recent Gains May Please Fulgent Genetics, Inc. (NASDAQ:FLGT) Institutional Owners
All You Need to Know About Fulgent Genetics (FLGT) Rating Upgrade to Strong Buy
Fulgent Genetics Is Maintained at Neutral by Piper Sandler
Fulgent Genetics Analyst Ratings
Piper Sandler Maintains Fulgent Genetics(FLGT.US) With Hold Rating, Cuts Target Price to $22
Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript Summary
Coach Donnie : Let’s GOOO